World's Best Scientists 2026 revealed!

D-Index & Metrics

Biology and Biochemistry

D-Index
68
Citations
27867
World Ranking
7625
National Ranking
3468

Saul H. Rosenberg publication distribution in Biology and Biochemistry in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Biology and Biochemistry in 2026. The highlighted bar marks where Saul H. Rosenberg sits on this spectrum.

47–56 publications: 8 scientists 57–66 publications: 35 scientists 67–76 publications: 106 scientists 77–86 publications: 231 scientists 87–96 publications: 414 scientists 97–106 publications: 546 scientists 107–116 publications: 704 scientists 117–126 publications: 849 scientists 127–136 publications: 980 scientists 137–146 publications: 942 scientists 147–156 publications: 969 scientists 157–166 publications: 950 scientists 167–176 publications: 951 scientists 177–186 publications: 915 scientists 187–196 publications: 787 scientists 197–206 publications: 841 scientists 207–216 publications: 735 scientists 217–226 publications: 709 scientists 227–236 publications: 651 scientists 237–246 publications: 605 scientists 247–256 publications: 510 scientists 257–266 publications: 524 scientists 267–276 publications: 434 scientists 277–286 publications: 418 scientists 287–296 publications: 350 scientists 297–306 publications: 363 scientists 307–316 publications: 315 scientists 317–326 publications: 296 scientists 327–336 publications: 261 scientists 337–346 publications: 240 scientists 347–356 publications: 219 scientists 357–366 publications: 197 scientists 367–376 publications: 154 scientists 377–386 publications: 161 scientists 387–396 publications: 155 scientists 397–406 publications: 145 scientists 407–416 publications: 124 scientists 417–426 publications: 112 scientists 427–436 publications: 132 scientists 437–446 publications: 116 scientists 447–456 publications: 99 scientists 457–466 publications: 81 scientists 467–476 publications: 91 scientists 477–486 publications: 80 scientists 487–496 publications: 80 scientists 497–506 publications: 60 scientists 507–516 publications: 36 scientists 517–526 publications: 46 scientists 527–536 publications: 54 scientists 537–546 publications: 44 scientists 547–556 publications: 43 scientists 557–566 publications: 43 scientists 567–576 publications: 42 scientists 577–586 publications: 25 scientists 587–596 publications: 34 scientists 597–606 publications: 23 scientists 607–616 publications: 33 scientists 617–626 publications: 31 scientists 627–636 publications: 27 scientists 637–646 publications: 25 scientists 647–656 publications: 28 scientists 657–666 publications: 34 scientists 667–676 publications: 18 scientists 677–686 publications: 16 scientists 687–696 publications: 10 scientists 697–706 publications: 12 scientists 707–716 publications: 21 scientists 717–726 publications: 12 scientists 727–736 publications: 12 scientists 737–746 publications: 10 scientists 747–756 publications: 7 scientists 757–766 publications: 13 scientists 767–776 publications: 15 scientists 777–786 publications: 13 scientists 787–796 publications: 9 scientists 797–806 publications: 9 scientists 807–816 publications: 7 scientists 817–826 publications: 4 scientists 827–836 publications: 9 scientists 837–846 publications: 7 scientists 847–856 publications: 3 scientists 857–866 publications: 5 scientists 867–876 publications: 5 scientists 877–886 publications: 11 scientists 887–896 publications: 3 scientists 897–906 publications: 4 scientists 907–916 publications: 7 scientists 917–926 publications: 5 scientists 927–936 publications: 6 scientists 937–946 publications: 6 scientists 947–956 publications: 3 scientists 957–966 publications: 7 scientists 967–976 publications: 2 scientists 977–986 publications: 2 scientists 987–996 publications: 1 scientists 997–1,006 publications: 5 scientists 1,007–1,016 publications: 2 scientists 1,017–1,026 publications: 2 scientists 1,027 publications: 1 scientists 1,028+ publications: 100 scientists
47 publications 1,028+

This scientist: 244 publications — 65th percentile

65% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,028 publications or more.

Saul H. Rosenberg D-index placement in Biology and Biochemistry in 2026

The chart shows the D-index (discipline H-index) distribution of Biology and Biochemistry scientists ranked by Research.com in 2026. The highlighted bar marks where Saul H. Rosenberg sits on this spectrum.

40–41 D-Index: 80 scientists 42–43 D-Index: 183 scientists 44–45 D-Index: 317 scientists 46–47 D-Index: 504 scientists 48–49 D-Index: 718 scientists 50–51 D-Index: 900 scientists 52–53 D-Index: 1,026 scientists 54–55 D-Index: 1,150 scientists 56–57 D-Index: 1,236 scientists 58–59 D-Index: 1,253 scientists 60–61 D-Index: 1,163 scientists 62–63 D-Index: 1,131 scientists 64–65 D-Index: 1,032 scientists 66–67 D-Index: 897 scientists 68–69 D-Index: 814 scientists 70–71 D-Index: 715 scientists 72–73 D-Index: 709 scientists 74–75 D-Index: 596 scientists 76–77 D-Index: 512 scientists 78–79 D-Index: 473 scientists 80–81 D-Index: 412 scientists 82–83 D-Index: 373 scientists 84–85 D-Index: 358 scientists 86–87 D-Index: 285 scientists 88–89 D-Index: 273 scientists 90–91 D-Index: 227 scientists 92–93 D-Index: 208 scientists 94–95 D-Index: 193 scientists 96–97 D-Index: 153 scientists 98–99 D-Index: 157 scientists 100–101 D-Index: 148 scientists 102–103 D-Index: 120 scientists 104–105 D-Index: 113 scientists 106–107 D-Index: 100 scientists 108–109 D-Index: 86 scientists 110–111 D-Index: 67 scientists 112–113 D-Index: 72 scientists 114–115 D-Index: 73 scientists 116–117 D-Index: 64 scientists 118–119 D-Index: 53 scientists 120–121 D-Index: 60 scientists 122–123 D-Index: 54 scientists 124–125 D-Index: 43 scientists 126–127 D-Index: 38 scientists 128–129 D-Index: 49 scientists 130–131 D-Index: 26 scientists 132–133 D-Index: 18 scientists 134–135 D-Index: 23 scientists 136–137 D-Index: 32 scientists 138–139 D-Index: 32 scientists 140–141 D-Index: 27 scientists 142–143 D-Index: 19 scientists 144–145 D-Index: 22 scientists 146–147 D-Index: 12 scientists 148–149 D-Index: 16 scientists 150–151 D-Index: 14 scientists 152–153 D-Index: 10 scientists 154–155 D-Index: 13 scientists 156–157 D-Index: 10 scientists 158–159 D-Index: 7 scientists 160–161 D-Index: 9 scientists 162–163 D-Index: 13 scientists 164–165 D-Index: 4 scientists 166 D-Index: 4 scientists 167+ D-Index: 98 scientists
40 D-Index 167+

This scientist: 68 D-Index — 61st percentile

61% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 167 D-Index or more.

Overview

Saul H. Rosenberg is affiliated with AbbVie in the United States and has contributed extensively to research intersecting biochemistry, genetics, molecular biology, and medicine. Their work spans several subfields including molecular biology, hematology, oncology, computational theory and mathematics, as well as radiology, nuclear medicine, and imaging.

The research topics that Rosenberg has focused on include:

  • Protein degradation and inhibitors
  • Ubiquitin and proteasome pathways
  • Multiple myeloma research and treatments
  • Cancer-related gene regulation
  • Computational drug discovery methods
  • Histone deacetylase inhibitors research
  • CAR-T cell therapy research

Their recent papers cover a range of high-impact topics and are published in notable scientific journals, including:

  • "Selective inhibition of the BD2 bromodomain of BET proteins in prostate cancer," 2020, Nature
  • "Target 2035 - update on the quest for a probe for every protein," 2021, RSC Medicinal Chemistry
  • "Discovery of a Potent and Selective Covalent p300/CBP Inhibitor," 2021, ACS Medicinal Chemistry Letters
  • "Expanding the Repertoire for "Large Small Molecules": Prodrug ABBV-167 Efficiently Converts to Venetoclax with Reduced Food Effect in Healthy Volunteers," 2021, Molecular Cancer Therapeutics
  • "BCL-X L -targeting antibody-drug conjugates are active in preclinical models and mitigate on-mechanism toxicity of small-molecule inhibitors," 2024, Science Advances

Rosenberg frequently collaborates with several coauthors, including Chaohong Sun, Chang H. Park, Zhi-Fu Tao, Nathaniel D. Catron, and Russell A. Judge, each having coauthored at least two publications with Rosenberg.

In terms of publication venues, Rosenberg's work appears in:

  • Nature
  • RSC Medicinal Chemistry
  • ACS Medicinal Chemistry Letters
  • Science Advances
  • Molecular Cancer Therapeutics

Best Publications

  • An inhibitor of Bcl-2 family proteins induces regression of solid tumours

    Tilman Oltersdorf;Steven W. Elmore;Alexander R. Shoemaker;Robert C. Armstrong

  • ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets

    Andrew J Souers;Joel D Leverson;Erwin R Boghaert;Scott L Ackler

  • ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor

    Christin Tse;Alexander R. Shoemaker;Jessica Adickes;Mark G. Anderson

  • Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity

    Wyndham H Wilson;Owen A O'Connor;Myron S Czuczman;Ann S LaCasce

  • ABT-888, an Orally Active Poly(ADP-Ribose) Polymerase Inhibitor that Potentiates DNA-Damaging Agents in Preclinical Tumor Models

    Cherrie K. Donawho;Yan Luo;Yanping Luo;Thomas D. Penning

  • The promise and peril of chemical probes.

    Cheryl H. Arrowsmith;James E. Audia;Christopher Austin;Jonathan Baell

  • Discovery of a selective catalytic p300/CBP inhibitor that targets lineage-specific tumours.

    Loren M. Lasko;Clarissa G. Jakob;Rohinton P. Edalji;Wei Qiu

  • Potent, Orally Active Heterocycle-Based Combretastatin A-4 Analogues: Synthesis, Structure−Activity Relationship, Pharmacokinetics, and In Vivo Antitumor Activity Evaluation

    Le Wang;Keith W. Woods;Qun Li;Kenneth J. Barr

  • Bcl-2 family proteins are essential for platelet survival

    H Zhang;P M Nimmer;S K Tahir;J Chen

  • Chk1 mediates S and G2 arrests through Cdc25A degradation in response to DNA-damaging agents.

    Zhan Xiao;Zehan Chen;Angelo H. Gunasekera;Thomas J. Sowin

  • Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy

    Joel D. Leverson;Darren C. Phillips;Michael J. Mitten;Erwin R. Boghaert

  • Discovery of potent antagonists of the antiapoptotic protein XIAP for the treatment of cancer.

    Thorsten K Oost;Chaohong Sun;Robert C Armstrong;Ali-Samer Al-Assaad

  • Distinctive Roles of PHAP Proteins and Prothymosin-α in a Death Regulatory Pathway

    Xuejun Jiang;Hyun-Eui Kim;Hyun-Eui Kim;Hongjun Shu;Yingming Zhao

  • Potent and selective small-molecule MCL-1 inhibitors demonstrate on-target cancer cell killing activity as single agents and in combination with ABT-263 (navitoclax).

    J D Leverson;H Zhang;J Chen;S K Tahir

  • Influence of Bcl-2 Family Members on the Cellular Response of Small-Cell Lung Cancer Cell Lines to ABT-737

    Stephen K. Tahir;Xiufen Yang;Mark G. Anderson;Susan E. Morgan-Lappe

  • Discovery of a Potent Inhibitor of the Antiapoptotic Protein Bcl-xL from NMR and Parallel Synthesis

    Andrew M. Petros;Jurgen Dinges;David J. Augeri;Steven A. Baumeister

  • Potent and selective inhibitors of Akt kinases slow the progress of tumors in vivo.

    Yan Luo;Alexander R. Shoemaker;Xuesong Liu;Keith W. Woods

  • Discovery of an orally bioavailable small molecule inhibitor of prosurvival B-cell lymphoma 2 proteins.

    Cheol-Min Park;Milan Bruncko;Jessica Adickes;Joy Bauch

  • Selective inhibition of the BD2 bromodomain of BET proteins in prostate cancer

    Emily J. Faivre;Keith F. McDaniel;Daniel H. Albert;Srinivasa R. Mantena

  • Down-regulation of survivin by antisense oligonucleotides increases apoptosis, inhibits cytokinesis and anchorage-independent growth.

    Jun Chen;Wei Wu;Stephen K. Tahir;Paul E. Kroeger

Frequent Co-Authors

Hing L. Sham
Hing L. Sham Global Blood Therapeutics (United States)
Kennan C. Marsh
Kennan C. Marsh AbbVie (United States)
Eric F. Johnson
Eric F. Johnson AbbVie (United States)
Stephen W. Fesik
Stephen W. Fesik Vanderbilt University
Jun Chen
Jun Chen Nankai University
Andrew D. Hamilton
Andrew D. Hamilton New York University
Philip J. Hajduk
Philip J. Hajduk National Institutes of Health

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring Biology and Biochemistry in the USA opens doors to a range of rewarding online degrees and career pathways. Many students start by considering online biology degree programs, which offer flexibility and a solid foundation for further study or immediate entry into science careers.

For those interested in direct patient care, consider programs that prepare you for medical support roles. For example, online medical assistant programs fafsa approved allow you to gain clinical skills and financial aid eligibility, making them accessible and practical. If you’re already in this field, a medical assistant to lpn bridge program can help advance your qualifications and career prospects.

Nutrition is another growing niche. Aspiring nutritionists and dietitians can choose from a variety of specialized programs, including registered dietitian masters programs, which are highly valued by healthcare employers.

These diverse online pathways make it easier than ever to launch or advance your science career, wherever you are in your education or professional journey.

Best Scientists Citing Saul H. Rosenberg

Trending Scientists

Recently Published Articles